Vaccines, Blood & Biologics
Vaccines
Vaccines, as with all products regulated by FDA, undergo a rigorous review of laboratory and clinical data to ensure the safety, efficacy, purity and potency of these products. Vaccines approved for marketing may also be required to undergo additional studies to further evaluate the vaccine and often to address specific questions about the vaccine's safety, effectiveness or possible side effects.
According to the Centers for Disease Control and Prevention, vaccines have reduced preventable infectious diseases to an all-time low and now few people experience the devastating effects of measles, pertussis and other illnesses.
The Center for Biologics Evaluation and Research (CBER) regulates vaccine products. Many of these are childhood vaccines that have contributed to a significant reduction of vaccine-preventable diseases.
Vaccines Information
Vaccines Licensed for Immunization and Distribution in the US with Supporting Documents Biologics License Applications (BLA) Process (CBER) Vaccine and Related Biological Product Guidances Vaccine Notices, Proposed and Final Rules Vaccines and Related Biological Products Advisory Committee Questions about Vaccines Vaccines
FDA Consumer UpdatesCDC National Immunization Program
Centers for Disease Control and Prevention
Vaccine Safety & Availability
Common Ingredients in U.S. Licensed Vaccines Vaccine Adverse Events
Report adverse events (side effects) related to the administration of U.S. licensed vaccinesVaccine Safety & Availability Influenza Virus Vaccine Safety & Availability Vaccine Safety Questions and Answers Recommendations for the Use of Vaccines Manufactured with Bovine-Derived Materials Thimerosal in Vaccines FDA and CDC Issue Alert on Menactra Meningococcal Vaccine and Guillain Barre Syndrome
FDA Press Release, September 30, 2005MMWR - Guillain-Barr� Syndrome Among Recipients of Menactra Meningococcal Conjugate Vaccine
MMWR Weekly Report, Centers for Disease Control, October 20, 2006Institute of Medicine (IOM) - Immunization Safety Review: Vaccines and Autism 
Seasonal Information
Get Set for Winter Illness Season Think flu shots, hand-washing, and choosing OTC medications carefully Influenza Virus Vaccine Safety & Availability
Slide Presentations - U.S. Regulatory Perspective on Preventive Vaccine Development
October 30, 2007
IND Overview (PDF - 409KB)
LCDR Vada PerkinsRegulatory Considerations for the Manufacture of Investigational Vaccines for Clinical Trials (PDF - 495KB)
CDR Jon R. Daugherty, PhDRegulatory Aspects of the Nonclinical Safety Assessment of Adjuvanted Preventive Vaccines (PDF - 453KB)
Steven Kunder, PhD, DABTRegulatory Perspective on Development of Preventive Vaccines for Global Infectious Diseases (PDF - 618KB)Rosemary Tiernan, MD, MPH
Contact FDA
Division of Communication and Consumer Affairs
Office of Communication, Outreach and Development
Food and Drug Administration
1401 Rockville Pike
Suite 200N/HFM-47
Rockville, MD 20852-1448
